Home > Core technology > Next-Generation Autologous CAR-T Cell Therapy Technology
The company's proprietary next-generation autologous CAR-T features a unique CAR construct conferring superior proliferative capacity and anti-exhaustion properties, with a mild onset profile and prolonged in vivo persistence. It can overcome the immunosuppressive effects of the solid tumor microenvironment and kill tumor cells more effectively. The products are manufactured using the company's globally pioneering scalable high-purity retrovirus, delivering higher purity and efficacy, enhanced safety, low production costs, and competitive market pricing. It is expected to be included in national medical insurance, presenting substantial commercial value.